Kim HC, Kang YR, Ji W, et al. - In this retrospective review, researchers intended to gain knowledge about BRAF mutations in non-small cell lung cancer patients without EGFR/ALK aberrations. A comparison was performed, in terms of outcomes, between stage III/IV adenocarcinoma patients (n=224) without EGFR/ALK aberrations and with available pathologic tissue and stage III/IV adenocarcinoma patients with an EGFR mutation from a recent previous study. They analyzed a cohort comprising 222 adenocarcinoma patients with adequate pathologic tissue samples. Four patients (1.8%) had V600E BRAF mutation present. A poorer survival outcome was observed in 222 study patients vs stage III/IV adenocarcinoma patients with an EGFR mutation from a recent previous study. In this study, although 1.8% of advanced adenocarcinoma patients without EGFR/ALK aberration had BRAF mutations, these mutations could be a treatment target in those patients.